<DOC>
	<DOC>NCT00389064</DOC>
	<brief_summary>The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve elderly patients with generalised anxiety disorder. PLEASE NOTE: Seroquel SR and Seroquel extended release(XR) refer to the same formulation. The SR designation was changed to XR after consultation with FDA.</brief_summary>
	<brief_title>Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Male or female patients, 66 years or older, with a documented clinical diagnosis of Generalised Anxiety Disorder (GAD). Absence of current episode of major depression. The presence of dementia or other mental disorder than GAD. Serious suicidal risk, uncontrolled hypertension, substance or alcohol abuse. A current diagnosis of cancer or current or past diagnosis of stroke.</criteria>
	<gender>All</gender>
	<minimum_age>66 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Generalised Anxiety Disorder</keyword>
	<keyword>GAD</keyword>
</DOC>